Page last updated: 2024-11-06

loganin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Loganin is a naturally occurring iridoid glycoside found in various plants, notably in the genus *Strychnos*. It is known for its diverse pharmacological properties, including anti-inflammatory, anti-oxidant, and anti-cancer activities. Loganin is a precursor to various other important natural products, such as secologanin, which is involved in the biosynthesis of indole alkaloids. Research on loganin focuses on its potential applications in medicinal chemistry, particularly in the development of new drugs for treating various ailments. Its biosynthesis involves the enzymatic conversion of geraniol to loganin. Studies have shown that loganin exhibits anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines, while its antioxidant activity is attributed to its ability to scavenge free radicals. Additionally, loganin has demonstrated potential anti-cancer activity through mechanisms like apoptosis induction and cell cycle arrest. The compound's importance lies in its multifaceted pharmacological properties and its role as a precursor in the biosynthesis of other bioactive compounds.'

Cross-References

ID SourceID
PubMed CID87691
CHEMBL ID1081584
CHEBI ID15771
SCHEMBL ID307017
MeSH IDM0165535

Synonyms (79)

Synonym
nsc-606403
1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta[c]pyran-4-carboxylic acid methyl ester
CHEBI:15771 ,
methyl (1s,4as,6s,7r,7as)-1-(beta-d-glucopyranosyloxy)-6-hydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
DIVK1C_006659
SDCCGMLS-0066747.P001
SPECTRUM_001503
SPECTRUM4_001914
SPECTRUM5_000628
MEGXP0_000723
ACON1_001749
BSPBIO_003350
C01433
18524-94-2
loganin ,
KBIO2_001983
KBIOGR_002535
KBIO2_007119
KBIOSS_001983
KBIO2_004551
KBIO3_002852
KBIO1_001603
SPBIO_001733
SPECPLUS_000563
SPECTRUM3_001875
SPECTRUM2_001637
SPECTRUM1504066
NCGC00178124-02
NCGC00178124-01
LMPR0102070001
5A5AFFBA-93AB-4635-A071-FC87B9DC023D
methyl (1s,4as,6s,7r,7as)-6-hydroxy-7-methyl-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
CHEMBL1081584
methyl (1s,4as,6s,7r,7as)-6-hydroxy-7-methyl-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
unii-h7wj16q93c
einecs 242-398-0
methyl (1s-(1alpha,4aalpha,6alpha,7alpha,7aalpha))-1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta(c)pyran-4-carboxylate
h7wj16q93c ,
nsc 606403
methyl 6-hydroxy-7-methyl-1-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5
6-hydroxy-7-methyl-1-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid methyl ester
A812937
cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1s, 4as, 6s, 7r, 7as)-
S3835
CCG-38757
7-hydroxy-6-desoxyverbenalin
(-)-loganin
SCHEMBL307017
AKOS022190418
(1s)-1.alpha.-(.beta.-d-glucopyranosyloxy)-1,4a.alpha.,5,6,7,7a.alpha.-hexahydro-6.alpha.-hydroxy-7.alpha.-methylcyclopenta(c)pyran-4-carboxylic acid methyl ester
loganin [mi]
loganin, (-)-
cyclopenta(c)pyran-4-carboxylic acid, 1-(.beta.-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester
cyclopenta(c)pyran-4-carboxylic acid, 1-(.beta.-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1s-(1.alpha.,4a.alpha.,6.alpha.,7.alpha.,7a.alpha.))-
methyl (1s-(1.alpha.,4a.alpha.,6.alpha.,7.alpha.,7a.alpha.))-1-(.beta.-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta(c)pyran-4-carboxylate
cyclopenta(c)pyran-4-carboxylic acid, 1-(.beta.-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1s,4as,6s,7r,7as)-
CS-5019
methyl (1s,4as,6s,7r,7as)-6-hydroxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
c17h26o10
AC-34479
Q-100220
HY-N0512
cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1s-(1alpha,4aalpha,6alpha,7alpha,7aalpha))-
loganin, analytical standard
meliatin
NCGC00178124-04
(1s,4as,6s,7r,7as)-methyl 6-hydroxy-7-methyl-1-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
(1s,4as,6s,7r,7as)-methyl 6-hydroxy-7-methyl-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
AS-75232
AMBQHHVBBHTQBF-UOUCRYGSSA-N
Q15426222
cyclopenta[c]pyran-4-carboxylic acid,1-(b-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1s,4as,6s,7r,7as)-
bdbm50279529
(1s,4as,6s,7r,7as)-methyl6-hydroxy-7-methyl-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester
1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta(c)pyran-4-carboxylic acid methyl ester
cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1s,4as,6s,7r,7as)-
(1s)-1alpha-(beta-d-glucopyranosyloxy)-1,4aalpha,5,6,7,7aalpha-hexahydro-6alpha-hydroxy-7alpha-methylcyclopenta(c)pyran-4-carboxylic acid methyl ester
methyl (1s,4as,6s,7r,7as)-1-(beta-d-glucopyranosyloxy)-6-hydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta(c)pyran-4-carboxylate

Research Excerpts

Overview

Loganin is a major iridoid glycoside obtained from the traditional Chinese herb Corni Fructus. Loganin has antioxidant, anti-inflammatory, glucose-lowering activities which may address the pathological mechanisms of painful diabetic neuropathy.

ExcerptReferenceRelevance
"Loganin is an iridoid glycoside with antioxidant, anti-inflammatory, glucose-lowering activities which may address the pathological mechanisms of painful diabetic neuropathy (PDN) related to inflammation, oxidative stress, and hyperglycemia. "( Loganin Ameliorates Painful Diabetic Neuropathy by Modulating Oxidative Stress, Inflammation and Insulin Sensitivity in Streptozotocin-Nicotinamide-Induced Diabetic Rats.
Cheng, YC; Chiu, YM; Dai, ZK; Wu, BN, 2021
)
3.51
"Loganin is a major iridoid glycoside obtained from the traditional Chinese herb Corni Fructus."( Loganin improves chronic unpredictable mild stress-induced depressive-like behaviors and neurochemical dysfunction.
Guo, YX; Han, Y; He, J; Shi, R; Wang, YM; Wang, ZX; Xia, CY; Xu, JK; Yan, Y; Zhang, WK, 2023
)
3.07
"Loganin is an iridoid glycoside extracted from traditional Chinese medicines, which has multiple activities."( Loganin alleviates myocardial ischemia-reperfusion injury through GLP-1R/NLRP3-mediated pyroptosis pathway.
Fan, P; Li, W; Tang, H; Wang, X, 2023
)
3.07
"Loganin is an iridoid with potent pharmacological effects. "( Identification of intestinal metabolic activation of loganin generated dialdehyde reactive intermediates improves intestinal bile salt hydrolase activities.
Jin, J; Luo, Q; Shi, F, 2023
)
2.6
"Loganin is a major iridoid glycoside and one of the quality control indexes of CF."( Loganin ameliorates cartilage degeneration and osteoarthritis development in an osteoarthritis mouse model through inhibition of NF-κB activity and pyroptosis in chondrocytes.
Chen, D; Chen, Q; Du, W; Fu, F; Hu, J; Jin, H; Ruan, H; Tong, P; Wu, C; Wu, J; Yao, S; Yu, H; Zhou, J, 2020
)
2.72
"Loganin is a well-known herbal medicine with glucose-lowering action and neuroprotective activity."( Loganin prevents chronic constriction injury-provoked neuropathic pain by reducing TNF-α/IL-1β-mediated NF-κB activation and Schwann cell demyelination.
Chang, YC; Chen, JY; Cheng, KI; Cheng, YC; Chu, LW; Dai, ZK; Hsu, JH; Wu, BN; Yeh, JL, 2020
)
2.72
"Loganin is a major iridoid glycoside isolated from Corni fructus that has been used as an anti-inflammatory agent in various pathological models."( Loganin Attenuates the Severity of Acute Kidney Injury Induced by Cisplatin through the Inhibition of ERK Activation in Mice.
Bae, GS; Choi, JW; Kim, DG; Kim, DU; Kweon, B; Lee, HS; Park, SJ; Shin, JY; Song, HJ; Zhou, Z, 2021
)
2.79
"Loganin is an iridoid glycoside isolated from Corni fructus and exerts an anti-inflammatory effect in multiple inflammatory diseases; however, the role of loganin in sepsis-induced ALI remains unknown."( Loganin alleviates sepsis-induced acute lung injury by regulating macrophage polarization and inhibiting NLRP3 inflammasome activation.
Li, X; Wang, C; Wang, H; Xu, J; Yu, K; Zhang, J, 2021
)
2.79
"Loganin is an iridoid glycoside that has been shown to alleviate a variety of cytotoxic effects."( Blocking Smad2 signalling with loganin attenuates SW10 cell cycle arrest induced by TNF-α.
Chao, G; Cong, F; Ou, X; Song, T; Tian, X; Zhang, W, 2017
)
1.46
"Loganin is a botanical candidate with anti-inflammatory, anti-oxidant, glucose-lowering and anti-diabetic nephropathy activities."( Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy.
Chang, FR; Chen, CS; Jong, YJ; Lo, YC; Tseng, YT, 2016
)
2.6
"Loganin is a major iridoid glycoside obtained from Corni fructus (Cornusofficinalis et Zucc) and demonstrated to have anti-inflammatory, anti-tumor and osteoporosis prevention effects."( Loganin enhances long-term potentiation and recovers scopolamine-induced learning and memory impairments.
Han, SM; Hwang, ES; Kim, HB; Kim, MJ; Lee, S; Lee, SO; Maeng, S; Park, JH, 2017
)
2.62
"Loganin is an iridoid glycoside found in the Flos lonicerae, Fruit cornus, and Strychonos nux vomica. "( Loganin improves learning and memory impairments induced by scopolamine in mice.
Jang, CG; Kim, HC; Kwon, SH; Lee, SY, 2009
)
3.24
"Loganin is an important constituent of the traditional Chinese medicine Fructus Corni, with several bioactivities. "( Microbial metabolism of loganin by intestinal bacteria and identification of new metabolites in rat.
Huo, C; Li, X; Sheng, X; Wang, Q; Zhang, L; Zhang, X, 2008
)
2.1

Effects

Loganin has been shown to improve depression-like behavior in mice exposed to acute stress. Loganin has potential medicinal value in alleviating neuroinflammation.

ExcerptReferenceRelevance
"Loganin has been widely concerned due to its extensive pharmacological effects, including anti-diabetic, antiinflammatory, neuroprotective, and anti-tumor activities, etc."( Phytochemistry, synthesis, analytical methods, pharmacological activity, and pharmacokinetics of loganin: A comprehensive review.
He, J; Li, L; Lian, WW; Peng, Y; Wang, YW; Xia, CY; Xu, JK; Yan, Y; Zhang, F; Zhang, J; Zhang, WK; Zheng, J, 2022
)
1.66
"Loganin, which has been shown to improve depression-like behavior in mice exposed to acute stress, is probably a potential antidepressant candidate."( Loganin improves chronic unpredictable mild stress-induced depressive-like behaviors and neurochemical dysfunction.
Guo, YX; Han, Y; He, J; Shi, R; Wang, YM; Wang, ZX; Xia, CY; Xu, JK; Yan, Y; Zhang, WK, 2023
)
3.07
"Loganin has potential medicinal value in alleviating neuroinflammation."( Loganin reduces neuroinflammation and promotes functional recovery after spinal cord injury through inhibiting NF-κB/NLRP3 signalling.
Chen, X; Huang, X; Li, Q; Ni, BH; Wang, W, 2023
)
3.07
"Loganin has been demonstrated to improve depression-like behavior and may be a potential antidepressant candidate."( Development and validation of a simple and rapid UPLC-MS/MS method for loganin and its application in pharmacokinetic and tissue distribution studies.
Ding, K; He, J; Li, L; Lian, WW; Wang, WP; Xia, CY; Xu, JK; Yan, Y; Yang, H; Zhang, F; Zhang, WK, 2024
)
2.4
"Loganin has been shown to have antioxidant and anti-inflammatory neuroprotective activities."( Loganin Attenuates High Glucose-Induced Schwann Cells Pyroptosis by Inhibiting ROS Generation and NLRP3 Inflammasome Activation.
Chang, YC; Chen, JY; Cheng, YC; Chu, LW; Dai, ZK; Hsieh, SL; Wu, BN, 2020
)
2.72
"Loganin has been proved to possess the property of anti-inflammation, antioxidant, neuroprotection, and sedation."( Loganin Attenuates Septic Acute Renal Injury with the Participation of AKT and Nrf2/HO-1 Signaling Pathways.
Jia, X; Kang, K; Liu, H; Liu, X; Wang, C; Yu, K; Zhang, J, 2021
)
2.79

Treatment

Loganin treatment also significantly restored body weight gain and attenuated blood glucose changes in the diabetic rats. In loganin-treated db/db mice, hyperglycemia and dyslipidemia were ameliorated in both the serum and hepatic tissue.

ExcerptReferenceRelevance
"Loganin treatment also significantly restored body weight gain and attenuated blood glucose changes in the diabetic rats."( Impact of loganin on pro-inflammatory cytokines and depression- and anxiety-like behaviors in male diabetic rats.
Babri, S; Farajdokht, F; Mesgari, M; Mohaddes, G; Nayebi Rad, S; Rajabi, M, 2018
)
1.6
"Loganin treatment also significantly restored body weight gain and attenuated blood glucose changes in the diabetic rats."( Impact of loganin on pro-inflammatory cytokines and depression- and anxiety-like behaviors in male diabetic rats.
Babri, S; Farajdokht, F; Mesgari, M; Mohaddes, G; Nayebi Rad, S; Rajabi, M, 2018
)
1.6
"In loganin-treated db/db mice, hyperglycemia and dyslipidemia were ameliorated in both the serum and hepatic tissue; however, in the kidney, only triglyceride was reduced."( Evaluation of loganin, iridoid glycoside from Corni Fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice.
Kang, KS; Noh, JS; Park, CH; Shibahara, N; Tanaka, T; Yamabe, N; Yokozawa, T, 2010
)
1.24
"Pre-treatment of loganin reduced pancreatic damage and AP-associated lung injury and attenuated the severity of AP, as evidenced by (1) a reduction in several biochemical parameters (pancreatic weight to body weight ratio, myeloperoxidase activity, and level of amylase) and (2) production of pro-inflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α."( Loganin protects against pancreatitis by inhibiting NF-κB activation.
Bae, GS; Choi, SB; Jo, IJ; Kim, DG; Kim, MJ; Lee, SK; Park, SJ; Shin, JY; Shin, S; Song, HJ, 2015
)
2.19
"Pretreatment with loganin significantly increased cell viability, reduced H(2)O(2)-induced LDH release and ROS production, and effectively increased intracellular MMP."( Loganin protects against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells.
Hong, SI; Jang, CG; Jung, YH; Kim, HC; Kim, JA; Kwon, SH; Lee, SY, 2011
)
2.14

Pharmacokinetics

The pharmacokinetic behavior of morroniside and loganin in normal and CKD rat plasma was determined in this paper. After a single intravenous administration of Cornus officinalis injection to mice, the mean plasma concentration-time courses were found to fit a two-compartment open model.

ExcerptReferenceRelevance
"It is the first time to establish the revered-phase HPLC method to determine concentrations of loganin and morroniside in plasma and to obtain their pharmacokinetic parameters and characteristics."( [Studies on pharmacokinetics of loganin and morroniside in Cornus officinalis injection in mice].
Ren, LM; Wun, JK; Zhang, LT, 2003
)
0.82
" The renal impairment may affect drug clearance and other pharmacokinetic processes which can increase toxicity and drug to drug interactions or cause ineffective therapy."( Comparative pharmacokinetics of the main compounds of Shanzhuyu extract after oral administration in normal and chronic kidney disease rats.
Du, L; Duan, JA; Guo, J; Jiang, S; Liu, P; Qian, D; Shang, EX; Su, SL; Tao, J; Zhao, M, 2015
)
0.42
"The pharmacokinetic behavior of morroniside and loganin in normal and CKD rat plasma was determined in this paper."( Comparative pharmacokinetics of the main compounds of Shanzhuyu extract after oral administration in normal and chronic kidney disease rats.
Du, L; Duan, JA; Guo, J; Jiang, S; Liu, P; Qian, D; Shang, EX; Su, SL; Tao, J; Zhao, M, 2015
)
0.67
" The method was successfully applied to pharmacokinetic study of the analytes in normal and doxorubicin-induced chronic kidney disease rat plasma."( Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC-MS for investigating the pharmacokinetics of Rehmannia glutinosa and Cornus officinalis Sieb drug pair extract.
Du, L; Duan, JA; Guo, J; Jiang, S; Liu, P; Qian, D; Shang, EX; Su, SL; Tao, J; Zhao, M, 2016
)
0.72
" However, the pharmacokinetic characteristics and tissue distribution of loganin, especially in the brain region, are still unclear."( Development and validation of a simple and rapid UPLC-MS/MS method for loganin and its application in pharmacokinetic and tissue distribution studies.
Ding, K; He, J; Li, L; Lian, WW; Wang, WP; Xia, CY; Xu, JK; Yan, Y; Yang, H; Zhang, F; Zhang, WK, 2024
)
1.91
"This study aims to investigate the pharmacokinetic characteristics and tissue distribution after oral administration of loganin in rats."( Development and validation of a simple and rapid UPLC-MS/MS method for loganin and its application in pharmacokinetic and tissue distribution studies.
Ding, K; He, J; Li, L; Lian, WW; Wang, WP; Xia, CY; Xu, JK; Yan, Y; Yang, H; Zhang, F; Zhang, WK, 2024
)
1.88
" Concentration-time data was subjected to pharmacokinetic analysis."( Development and validation of a simple and rapid UPLC-MS/MS method for loganin and its application in pharmacokinetic and tissue distribution studies.
Ding, K; He, J; Li, L; Lian, WW; Wang, WP; Xia, CY; Xu, JK; Yan, Y; Yang, H; Zhang, F; Zhang, WK, 2024
)
1.68

Bioavailability

ExcerptReferenceRelevance
" It has specific absorption locus and access to locating administration, meanwhile it's the P-gp substrate, and could increase its fraction of bioavailability by corporation with P-gp inhibitor."( [Studies on absorption mechanism of loganin in intestines of rats].
Hu, ZT; Ji, YB; Li, WL; Wang, XD; Xu, D, 2008
)
0.62
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"In order to optimize the base fertilizer dosage and root size of Gentiana crassicaulis in Ludian,Yulong, Yunnan,the differences in yield and quality of Gentiana crassicaulis caused by different base fertilizer dosage and root size were investigated."( [Influences of Base Fertilizer Dosage and Root Size on Quality and Yield of Gentiana crassicaulis Root].
Chen, XF; Cheng, T; Meng, J; Song, JH; Yang, WY; Zeng, Y, 2015
)
0.42
"There were big differences in yield and quality of Gentiana crassicaulis among different base fertilizer dosage and root size."( [Influences of Base Fertilizer Dosage and Root Size on Quality and Yield of Gentiana crassicaulis Root].
Chen, XF; Cheng, T; Meng, J; Song, JH; Yang, WY; Zeng, Y, 2015
)
0.42
" Mice were administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) with a dosage of 30 mg/kg daily for 5 days to establish a subacute PD model and treated with loganin."( Neuroprotective Effects of Loganin on MPTP-Induced Parkinson's Disease Mice: Neurochemistry, Glial Reaction and Autophagy Studies.
Chu, M; Cui, C; Lin, SL; Shen, YQ; Shi, YW; Sun, MF; Xu, YD; Yang, XS; Zhu, YL, 2017
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
EC 3.4.23.46 (memapsin 2) inhibitorAn EC 3.4.23.* (aspartic endopeptidase) inhibitor that interferes with the activity of memapsin 2 (EC 3.4.23.46).
EC 3.2.1.20 (alpha-glucosidase) inhibitorAn EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20).
anti-inflammatory agentAny compound that has anti-inflammatory effects.
EC 3.1.1.7 (acetylcholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
cyclopentapyran
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
enoate esterAn alpha,beta-unsaturated carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) in which the ester C=O function is conjugated to a C=C double bond at the alpha,beta position.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
iridoid monoterpenoidOne of a class of monoterpenoids biosynthesized from isoprene and often intermediates in the biosynthesis of alkaloids. Iridoids usually consist of a cyclopentane ring fused to a six-membered oxygen heterocycle; cleavage of a bond in the cyclopentane ring gives rise to the subclass known as secoiridoids.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
secologanin and strictosidine biosynthesis1336
Secologanin and strictosidine biosynthesis015

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Signal transducer and activator of transcription 3Homo sapiens (human)IC50 (µMol)14.00000.02304.13789.9800AID1504525
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Processvia Protein(s)Taxonomy
positive regulation of vascular endothelial growth factor productionSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
temperature homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
eye photoreceptor cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of DNA-templated transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
protein import into nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
signal transductionSignal transducer and activator of transcription 3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATSignal transducer and activator of transcription 3Homo sapiens (human)
nervous system developmentSignal transducer and activator of transcription 3Homo sapiens (human)
cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of autophagySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of gene expressionSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of gene expressionSignal transducer and activator of transcription 3Homo sapiens (human)
phosphorylationSignal transducer and activator of transcription 3Homo sapiens (human)
cytokine-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
sexual reproductionSignal transducer and activator of transcription 3Homo sapiens (human)
cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of cell migrationSignal transducer and activator of transcription 3Homo sapiens (human)
intracellular receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
response to estradiolSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-1 beta productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-10 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-6 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-8 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of tumor necrosis factor productionSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to hormone stimulusSignal transducer and activator of transcription 3Homo sapiens (human)
leptin-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
somatic stem cell population maintenanceSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-15-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-2-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-9-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-11-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
regulation of multicellular organism growthSignal transducer and activator of transcription 3Homo sapiens (human)
glucose homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
eating behaviorSignal transducer and activator of transcription 3Homo sapiens (human)
mRNA transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to leptin stimulusSignal transducer and activator of transcription 3Homo sapiens (human)
response to leptinSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of erythrocyte differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of Notch signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of angiogenesisSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of glycolytic processSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
astrocyte differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySignal transducer and activator of transcription 3Homo sapiens (human)
regulation of cell cycleSignal transducer and activator of transcription 3Homo sapiens (human)
radial glial cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
retinal rod cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of feeding behaviorSignal transducer and activator of transcription 3Homo sapiens (human)
growth hormone receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-6-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
T-helper 17 type immune responseSignal transducer and activator of transcription 3Homo sapiens (human)
T-helper 17 cell lineage commitmentSignal transducer and activator of transcription 3Homo sapiens (human)
energy homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to interleukin-17Signal transducer and activator of transcription 3Homo sapiens (human)
cell surface receptor signaling pathway via STATSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of inflammatory response to woundingSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-10-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of miRNA transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of metalloendopeptidase activitySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of primary miRNA processingSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of stem cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of neuron migrationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
response to peptide hormoneSignal transducer and activator of transcription 3Homo sapiens (human)
defense responseSignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingSignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificSignal transducer and activator of transcription 3Homo sapiens (human)
DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor activitySignal transducer and activator of transcription 3Homo sapiens (human)
nuclear receptor activitySignal transducer and activator of transcription 3Homo sapiens (human)
signaling receptor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein kinase bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein phosphatase bindingSignal transducer and activator of transcription 3Homo sapiens (human)
chromatin DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
signaling adaptor activitySignal transducer and activator of transcription 3Homo sapiens (human)
identical protein bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein homodimerization activitySignal transducer and activator of transcription 3Homo sapiens (human)
protein dimerization activitySignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
primary miRNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
lncRNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
RNA sequestering activitySignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
nucleoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
cytoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
cytosolSignal transducer and activator of transcription 3Homo sapiens (human)
plasma membraneSignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II transcription regulator complexSignal transducer and activator of transcription 3Homo sapiens (human)
chromatinSignal transducer and activator of transcription 3Homo sapiens (human)
transcription regulator complexSignal transducer and activator of transcription 3Homo sapiens (human)
cytoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID671428Inhibition of LPS-induced NF-KB transcriptional activity expressed in HEK-293 cells at 10 ug/ml after 4 hrs by luciferase reporter gene assay relative to LPS-treated group2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Iridoid glucosides and a C₁₃-norisoprenoid from Lamiophlomis rotata and their effects on NF-κB activation.
AID1504525Inhibition of IL-6-Induced STAT3 activation (unknown origin) expressed in human HepG2 cells expressing pSTAT3-luciferase pre-incubated for 1 hr before IL-6 stimulation for 6 hrs by luciferase reporter gene assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Cornusides A-O, Bioactive Iridoid Glucoside Dimers from the Fruit of Cornus officinalis.
AID467897Antiviral activity against HCV infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by NS5A staining2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID467894Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml measured after 72 hrs by luciferase reporter gene assay2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID1251040Inhibition of COX2 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID1251039Inhibition of COX2 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID467898Inhibition of human recombinant GST-tagged CD81 protein assessed as HCV E1E2 binding after 1 hr by Western blot analysis2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID1251036Inhibition of COX1 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID1251038Inhibition of COX1 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID671427Inhibition of LPS-induced NF-KB transcriptional activity expressed in HEK-293 cells at 1 ug/ml after 4 hrs by luciferase reporter gene assay relative to LPS-treated group2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Iridoid glucosides and a C₁₃-norisoprenoid from Lamiophlomis rotata and their effects on NF-κB activation.
AID1504526Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Cornusides A-O, Bioactive Iridoid Glucoside Dimers from the Fruit of Cornus officinalis.
AID1251041Inhibition of COX2 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID1545462Inhibition of beta secretase (unknown origin)
AID1251037Inhibition of COX1 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis.
AID671429Inhibition of LPS-induced NF-KB transcriptional activity expressed in HEK-293 cells at 100 ug/ml after 4 hrs by luciferase reporter gene assay relative to LPS-treated group2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Iridoid glucosides and a C₁₃-norisoprenoid from Lamiophlomis rotata and their effects on NF-κB activation.
AID467895Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay in presence of beta-glucosidase enzyme for 0.5 h2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID467896Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay in presence of beta-glucosidase enzyme for 4 hrs2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (154)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.30)18.7374
1990's3 (1.95)18.2507
2000's34 (22.08)29.6817
2010's71 (46.10)24.3611
2020's44 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.66 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other153 (98.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]